DUBLIN--(BUSINESS WIRE)--The "Gastro-esophageal Adenocarcinoma - Epidemiology Forecast - 2030" report has been added to ResearchAndMarkets.com's offering.
This report delivers an in-depth understanding of the Gastro-esophageal Adenocarcinoma, historical and forecasted epidemiology as well as the Gastro-esophageal Adenocarcinoma trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Gastro-esophageal Adenocarcinoma Understanding
Gastroesophageal adenocarcinoma includes esophageal adenocarcinoma, gastroesophageal junctional adenocarcinoma, and gastric adenocarcinoma. There is an increasing trend in the incidence of these cancers in the 7MM.
Gastroesophageal cancer (GEC), comprising proximal esophagogastric junction (EGJ) and distal gastric cancer (GC), is a significant public health concern. The epidemiology of these tumors has significantly changed over the past several decades especially in developed countries. There is a recognized decrease in incidence and mortality of distal GC and an increase in incidence and mortality of proximal EGJ cancer.
Anatomically, gastroesophageal cancer (GEC) is comprised of two recognized tumor types, according to the 2010 American Joint Committee on Cancer (AJCC) TNM staging system. The first is esophageal/esophagogastric adenocarcinoma, herein referred to as EGJ cancers, entailing tumors arising between 5 cm proximal to the z-line (the endoscopic landmark demarcating the esophagus/stomach boundary) and 5 cm distal to the z-line into the stomach (gastric cardia). The EGJ encompasses the traditional Siewert EGJ classifications I, II, and III. Type I Siewert EGJ is considered esophageal adenocarcinoma. The second recognized tumor type is gastric adenocarcinoma (GC), also termed 'non-cardia' GC, referring to tumors arising anywhere 5 cm distal from the z-line to the pylorus.
Gastro-esophageal Adenocarcinoma Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Total Incident Cases of Gastro-esophageal Adenocarcinoma, Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma, and HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.
Gastro-esophageal Adenocarcinoma Detailed Epidemiology Segmentation
- As per this analysis, there was a total of 211,383 Gastro-esophageal Adenocarcinoma incident cases in 2020, increasing at a CAGR of 1.54% for the study period 2018-2030.
- Japan showed the highest incident population of Gastro-esophageal Adenocarcinomas, as compared to other 7MM countries in 2020 which was 115,627.
- Among the European 5 countries, Germany had the highest incident population of Gastro-esophageal Adenocarcinoma with 13,881 cases, followed by the United Kingdom with 13,366 cases, in 2020.
- The epidemiology model for Gastro-esophageal Adenocarcinoma estimates that out of the total incident population of 40,423 cases in the US, in 2020, 29,480 and 10,943 cases were contributed by males and females, respectively.
- In 2020, the incident cases of Gastro-esophageal Adenocarcinoma in Stage IV were 18,318. Remaining Stage I, Stage II, and Stage III contributed to 6,872, 5,838, and 7,793 cases from the total incident cases.
- In 2020, the grade-specific incident cases for Grade I, Grade II, Grade III, and Grade IV were 1,617, 10,237, 25,284, and 808, in the US.
- HER2 positive Gastro-esophageal Adenocarcinomas was found in 7,648 incident cases in the United States, in 2020.
Scope of the Report
- The report covers the descriptive overview of Gastro-esophageal Adenocarcinoma, explaining its causes, genomics, staging, and other parameters.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of Gastro-esophageal Adenocarcinoma.
- The report helps to recognize the growth opportunities in the 7MM with respect to the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM by Total Incident Cases of Gastro-esophageal Adenocarcinoma, Gender-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Stage-specific Incident Cases of Gastro-esophageal Adenocarcinoma, Grade-specific Incident Cases of Gastro-esophageal Adenocarcinoma, and HER2 Positive Incident Cases of Gastro-esophageal Adenocarcinoma.
Reasons to Buy
The Gastro-esophageal Adenocarcinoma report will allow the user to -
- Develop business strategies by understanding the trends shaping and driving the 7MM Gastro-esophageal Adenocarcinoma epidemiology forecast.
- The Gastro-esophageal Adenocarcinoma epidemiology report and model were written and developed by Masters and Ph.D. level epidemiologists.
- The Gastro-esophageal Adenocarcinoma epidemiology model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over the eleven-year forecast period using reputable sources.
For more information about this report visit https://www.researchandmarkets.com/r/am7kcq
